- Home
- NATH vs ENGN Comparison
NATH vs ENGN Comparison
Compare NATH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NATH | ENGN |
|---|---|---|
| Founded | 1916 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.8M | 647.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | NATH | ENGN |
|---|---|---|
| Price | $100.81 | $7.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 28.6K | ★ 520.7K |
| Earning Date | 02-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.29 | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.11 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.00 | $2.66 |
| 52 Week High | $118.32 | $12.25 |
Technical Indicators
Market Signals| Indicator | NATH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 33.65 |
| Support Level | $100.25 | $6.18 |
| Resistance Level | $101.86 | $7.33 |
| Average True Range (ATR) | 0.47 | 0.66 |
| MACD | -0.10 | -0.14 |
| Stochastic Oscillator | 55.26 | 15.24 |
Price Performance
Historical ComparisonAbout NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.